Context Therapeutics INC 8-K filings

Context Therapeutics Inc. received a notice from Nasdaq for failing to meet the Minimum Bid Price Rule, with 180 days to regain compliance.

Context Therapeutics stockholders approved an increase in authorized common stock from 200 million to 300 million shares.

Context Therapeutics announces encouraging interim Phase 1 data for CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, showing a 29% ORR in platinum-resistant ovarian cancer.

Context Therapeutics has amended its license agreement with BioAtla for CT-202, eliminating future milestone and royalty payments in exchange for a $6.5 million payment and securing irrevocable rights to the bispecific antibody.

Context Therapeutics has finalized the resolution of a stockholder class action lawsuit through a third-party funded mootness fee payment.

Context Therapeutics Inc. updated its corporate presentation, highlighting its T-cell engager pipeline for solid tumors and projecting a cash runway into mid-2027.

Context Therapeutics Inc. has amended its corporate charter, invalidating three-year director terms and 'for cause' removal provisions following a Delaware court judgment, enhancing shareholder governance.

Context Therapeutics Inc. has reached a proposed settlement in a stockholder class action, agreeing to invalidate certain charter provisions regarding director terms and removal.

Context Therapeutics Inc. updated investors on its T-cell engager pipeline for solid tumors, highlighting positive preliminary Phase 1a data for CTIM-76 and outlining key milestones for 2026.

Context Therapeutics Inc. announced its third quarter 2025 operating and financial results, highlighting encouraging preliminary anti-tumor activity and safety in its CTIM-76 Phase 1 trial and progress in other T cell engager programs.

Context Therapeutics Inc. amended its at-the-market sales agreement with Leerink Partners LLC, increasing the potential aggregate offering to an additional $75.0 million for general corporate purposes and R&D.

Context Therapeutics Inc. announced it has regained compliance with Nasdaq's minimum bid price rule, closing the matter with the exchange.

Context Therapeutics Inc. received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price rule, pushing the deadline to February 23, 2026.

Context Therapeutics Inc. announced that its stockholders approved a reverse stock split proposal and ratified CohnReznick LLP as its independent registered public accounting firm at the 2025 Annual Meeting.

Context Therapeutics Inc. has updated its corporate presentation, highlighting significant progress in its T-cell engager pipeline with two programs in Phase 1 clinical trials and a third nearing IND filing, supported by a cash runway into 2027.

Context Therapeutics announces the dosing of the first patient in its Phase 1 clinical trial evaluating CT-95, a mesothelin x CD3 T cell engaging bispecific antibody for solid tumors.

Context Therapeutics Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price rule, as its common stock price remained below $1.00 for 30 consecutive business days.

Context Therapeutics has dosed the first patient in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody, for CLDN6-positive gynecologic and testicular cancers.

Context Therapeutics has appointed Andy Pasternak as Chairman of the Board, succeeding Richard Berman, effective January 13, 2025.

Context Therapeutics Inc. has successfully raised approximately $15 million through the sale of common stock.

Context Therapeutics has entered into a sales agreement to potentially raise up to $75 million through an at-the-market offering of its common stock, aimed at funding research and development of its T-cell engager pipeline.

Context Therapeutics has secured an exclusive worldwide license from BioAtla to develop and commercialize a Nectin-4 x CD3 bispecific antibody, CT-202, for up to $133.5 million plus royalties.

Context Therapeutics Inc. successfully increased its authorized common stock from 100 million to 200 million shares after a special stockholder meeting on September 17, 2024.

Context Therapeutics has appointed Dr. Karen Smith and Dr. Luke Walker to its Board of Directors, bringing extensive experience in drug development and commercialization.

Context Therapeutics has acquired CT-95, a mesothelin x CD3 bispecific antibody, from Link Immunotherapeutics, adding a second clinical-stage T cell engager to its pipeline.

Context Therapeutics Inc. held its annual meeting on June 13, 2024, where stockholders voted on key proposals including the election of directors and ratification of the company's auditor.

Context Therapeutics has successfully raised $100 million through a private placement to fund the development of its clinical-stage product, CTIM-76, and extend its cash runway into 2028.

Context Therapeutics has submitted an Investigational New Drug application to the FDA for CTIM-76, a bispecific antibody targeting Claudin 6-positive tumors, marking a significant step towards clinical trials.

Context Therapeutics has amended its bylaws to reduce the quorum required for stockholder meetings and update procedures for director nominations.

Context Therapeutics has amended its licensing agreement with Integral Molecular, reducing future milestone payments for its CTIM-76 cancer therapy due to potential third-party intellectual property concerns.